Successful Polymyxin B Hemoperfusion Treatment Associated With Serial Reduction of Serum Anti-CADM-140/MDA5 Antibody Levels in Rapidly Progressive Interstitial Lung Disease With Amyopathic Dermatomyositis

Early Pulmonary Involvement of Anti-CADM-140 Autoantibody-positive Rapidly Progressive Interstitial Lung Disease Preceding Typical Cutaneous Symptoms

“…Similar HRCT findings of anti-CADM-140 autoantibodypositive RP-ILD as seen in our patient have been previously reported (8,9). In addition, Tanizawa et al evaluated HRCT features of 25 DM-ILD patients with (n=12) and without (n=13) anti-CADM-140 autoantibody (10).…”

“…The patient had a slight fever, cutaneous and mild respiratory symptoms, was treated with steroid pulse and immunosuppressive therapy and gradually improved. However, the patient developed respiratory failure and worsening bilateral GGO on chest CT afterward (9). Moreover, in the analysis of 21 anti-CADM-140 autoantibody-positive ILD cases, Tanizawa et al described that the overall survival of patients with lower consolidation/ GGO pattern on chest HRCT (similar to our case) was not significantly different from those with other HRCT patterns, although the 90-day mortality was significantly higher in those with a lower consolidation/GGO pattern (16).…”

Potential Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock Patients on Continuous Renal Replacement Therapy: A Propensity-Matched Analysis

“…Patients meeting the following criteria were excluded in order to ensure fair comparison between patients with and without PMX (list of ICD-10 code used to identify each condition is available on request from the authors): (i) end-stage renal disease (ESRD) at admission and/or the use of maintenance hemodialysis or peritoneal dialysis; (ii) records of cardiac intervention (cardiovascular surgery, percutaneous cardiac intervention, intra-aortic balloon pumping, or percutaneous veno-arterial extracorporeal membrane oxygenation), to exclude the condition where cardiogenic shock is more dominant than septic shock; (iii) started PMX before or after the day of CRRT initiation; (iv) received a diagnosis code indicative of viral, fungal, or Gram-positive bacterial infection, because PMX is generally not considered when physicians suspect sepsis due to infectious agents other than Gram-negative bacteria; (v) received intermittent RRT (IRRT) before CRRT, and (vi) received plasma exchange before CRRT, because prior use of these modalities might influence the need for PMX; (vii) acute pancreatitis and (viii) acute hepatic condition, because CRRT is used for acute pancreatitis and acute hepatic condition even without renal dysfunction under the Japanese health insurance system [30,31,32,33]; (ix) interstitial pneumonia, because PMX has been attempted preferentially for acute exacerbation of interstitial pneumonia without sepsis [7,34,35,36]. Among the eligible patients, patients who received PMX were identified.…”

Effects of Direct Hemoperfusion with Polymyxin B-immobilized Fiber on Rapidly Progressive Interstitial Lung Diseases

“…A novel autoantibody, anti-CADM-140, was identified and patients with the antibody frequently had ADM with rapidly progressive ILD (17). Teruya et al described an ADM patient who developed rapidly progressive ILD with elevated anti-CADM-140 autoantibody was successfully treated with PMX-DHP after being resistant to combined steroid and immunosuppressant therapy (18). Hara et al reported that PMX-DHP would be a safe and effective therapy for rapidly progressive ILDs of different etiologies that were resistant to initial high-dose glucocorticoid therapy (8).…”